Apellis Pharmaceuticals, Inc. (APLS) has entered a capped royalty purchase agreement with Sobi.
The deal allows Apellis to receive up to $300 million in exchange for 90% of its future ex-U.S. royalties for Aspaveli.
Swedish Orphan Biovitrum (SOBI) will pay $275 million in cash to acquire these royalties.
Additionally, Apellis is eligible for up to $25 million in milestone payments upon EMA approval of Aspaveli for C3G and IC-MPGN.
Timothy Sullivan, CFO of Apellis Pharmaceuticals, highlighted the transaction as a testament to their confidence in transforming treatment options for rare diseases.